The PTSD Checklist for DSM-5 (PCL-5) is a 20-item instrument that can be used to make a provisional diagnosis of PTSD based on DSM-5 criteria.
Find out more about PTSD Checklist for DSM-5
First used: 14 October 2021
PTSD is generally grouped alongside anxiety disorders given the similar symptomology that is experienced. There is estimated to be over 300 million people living with PTSD globally. MDMA holds significant promise for treating PTSD and is in Phase III of the clinical trial process,
Related PapersResponse to Intravenous Racemic Ketamine After Switch From Intranasal (S)-ketamine on Symptoms of Treatment-Resistant Depression and PTSD in Veterans: a Retrospective Case Series
This study retrospectively analyzed clinical outcomes in 15 veterans with comorbid treatment-resistant depression (TRD) and PTSD who initially received intranasal ketamine treatment before sitting to treatment with IV racemic ketamine. Both treatments led to significant reductions in measures of TRD and PTSD however, treatment with IV racemic ketamine led to greater reductions, suggesting that off-label use of IV racemic ketamine may be useful for those who do not respond adequately to FDA-approved intranasal ketamine.
Related TrialsFrontline Clinician Psilocybin Study
We aim to investigate the effects of a single dose of psilocybin, delivered in the context of pre- and post-dose psychotherapy, on symptoms of depression and burnout suffered by healthcare clinicians as a result of frontline work in the coronavirus disease of 2019 (COVID) pandemic.
A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD
This multi-site open-label study assesses the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in participants who were enrolled in a parent study for the treatment of posttraumatic stress disorder (PTSD).